Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Reddy Cheminor
Famotidine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Famotidine | EXPERIMENTAL | Famotidine tablets 40 mg of Dr. Reddy's |
| Pepcid | ACTIVE_COMPARATOR | Pepcid 40 mg Tablets of Merck \& Co., |
| Name | Type | Description |
|---|---|---|
| Famotidine | DRUG | Famotidine Tablets 40 mg |
| Pepcid | DRUG | 40mg tablets |
Inclusion Criteria: Exclusion Criteria: History or presence of significant: • cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease. In addition, history or presence of: * alcoholism or drug abuse within...
Famotidine is a small molecule drug developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. It is in Phase 1 clinical development. The specific medical conditions it is being studied for have not been disclosed.
Famotidine targets HRH2, also known as the histamine H2 receptor. It acts as an antagonist at this receptor, meaning it blocks the action of histamine at HRH2. This mechanism is the basis for its pharmacological activity.
Famotidine is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company whose shares trade under the ticker symbol RDY. The company is responsible for the clinical development of this asset.
Famotidine is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 1 program includes one completed trial.
Famotidine has been studied in one completed Phase 1 trial, NCT01511731, titled Bioavailability Study of Famotidine Tablets 40 mg Under Fasting Conditions. The trial enrolled 30 healthy male volunteers in Canada and was active-controlled and randomized.